GenEdit was founded to transform the delivery of gene therapies and enable the next generation of non-viral, gene editing-based therapeutics. GenEdit’s technology platform solves current delivery challenges by systematically screening its proprietary nanoparticle library and providing safer and efficient delivery to target tissues. GenEdit’s proprietary nanoparticles has broad applicability including the development of CRISPR-based therapeutics and gene therapy products for a wide range of genetic diseases.

Sorry. This page is not yet translated.
  • Consumer
  • Enterprise
  • All
  • Devices
  • Financial
  • Gaming
  • Healthcare
  • Marketplace
  • Media
  • Productivity
  • Search
  • Social
  • All
  • Apps & Services
  • Data & Analytics
  • Dev Tools
  • Hardware
  • Healthcare
  • Infrastructure
  • Marketing
  • Networking
  • Security
  • Storage
The Dentmakers.

Since 1972, we have partnered early and at every stage of growth with the founders of companies that now have an aggregate, public market value of over $3.3 trillion. Meet the companies below.

Select Categories
Filter By Partner
Viewing Companies